This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by D'Souza, S.
Right arrow Articles by Huygen, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D'Souza, S.
Right arrow Articles by Huygen, K.

 Previous Article  |  Next Article 

Infection and Immunity, July 2002, p. 3681-3688, Vol. 70, No. 7
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.7.3681-3688.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Improved Tuberculosis DNA Vaccines by Formulation in Cationic Lipids

S. D'Souza,1 V. Rosseels,1 O. Denis,1 A. Tanghe,1 N. De Smet,1 F. Jurion,1 K. Palfliet,1 N. Castiglioni,1 A. Vanonckelen,1 C. Wheeler,2 and K. Huygen1*

Mycobacterial Immunology, Pasteur Institute of Brussels, B1180 Brussels, Belgium, and,1 Vical, Inc., San Diego, California 921212

Received 26 December 2001/ Returned for modification 29 January 2002/ Accepted 3 April 2002

Mice were vaccinated with plasmid DNA (pDNA) encoding antigen 85A (Ag85A), Ag85B, or PstS-3 from Mycobacterium tuberculosis either in saline or formulated for intramuscular injections in VC1052:DPyPE (aminopropyl-dimethyl-myristoleyloxy-propanaminium bromide-diphytanoylphosphatidyl-ethanolamine) (Vaxfectin; Vical, Inc., San Diego, Calif.) or for intranasal instillations in GAP-DLRIE:DOPE (aminopropyl-dimethyl-bis-dodecyloxy-propanaminium bromide-dioleoylphosphatidyl-ethanolamine). These two novel cationic and neutral colipid formulations were previously reported to be effective adjuvants for pDNA-induced antibody responses. The levels of Ag85-specific total immunoglobulin G (IgG) and IgG isotypes were all increased 3- to 10-fold by formulation of pDNA in Vaxfectin. The level of production of splenic T-cell-derived Th1-type cytokines (interleukin-2 and gamma interferon) in response to purified Ag85 and to synthetic peptides spanning the entire Ag85A protein was also significantly higher in animals vaccinated with pDNA formulated in Vaxfectin. Cytolytic T-lymphocyte responses generated by pDNA encoding phosphate-binding protein PstS-3 in Vaxfectin were better sustained over time than were those generated by PstS-3 DNA in saline. Intranasal immunization with Ag85A DNA in saline was completely ineffective, whereas administration in GAP-DLRIE:DOPE induced a positive Th1-type cytokine response; however, the extent of the latter response was clearly lower than that obtained following intramuscular immunization with the same DNA dose. Combined intramuscular and intranasal administrations in cationic lipids resulted in stronger immune responses in the spleen and, more importantly, in the lungs as well. Finally, formulation in Vaxfectin increased the protective efficacy of the Ag85B DNA vaccine, as measured by reduced relative light unit counts and CFU counts in the spleen and lungs from mice challenged with bioluminescent M. tuberculosis H37Rv. These results may be of importance for future clinical use of DNA vaccines in humans.

* Corresponding author. Mailing address: Mycobacterial Immunology, Pasteur Institute of Brussels, 642 Engelandstr., B1180 Brussels, Belgium. Phone: 32.2.373.33.70. Fax: 32.2.373.33.67. E-mail: khuygen{at}pasteur.be.

Editor: J. D. Clements

Infection and Immunity, July 2002, p. 3681-3688, Vol. 70, No. 7
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.7.3681-3688.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Roupie, V., Romano, M., Zhang, L., Korf, H., Lin, M. Y., Franken, K. L. M. C., Ottenhoff, T. H. M., Klein, M. R., Huygen, K. (2007). Immunogenicity of Eight Dormancy Regulon-Encoded Proteins of Mycobacterium tuberculosis in DNA-Vaccinated and Tuberculosis-Infected Mice. Infect. Immun. 75: 941-949 [Abstract] [Full Text]  
  • Rosseels, V., Roupie, V., Zinniel, D., Barletta, R. G., Huygen, K. (2006). Development of Luminescent Mycobacterium avium subsp. paratuberculosis for Rapid Screening of Vaccine Candidates in Mice.. Infect. Immun. 74: 3684-3686 [Abstract] [Full Text]  
  • Ko, H.-J., Ko, S.-Y., Kim, Y.-J., Lee, E.-G., Cho, S.-N., Kang, C.-Y. (2005). Optimization of Codon Usage Enhances the Immunogenicity of a DNA Vaccine Encoding Mycobacterial Antigen Ag85B. Infect. Immun. 73: 5666-5674 [Abstract] [Full Text]  
  • Diaz, M., Esteban, A., Fernandez-Abalos, J. M., Santamaria, R. I. (2005). The high-affinity phosphate-binding protein PstS is accumulated under high fructose concentrations and mutation of the corresponding gene affects differentiation in Streptomyces lividans. Microbiology 151: 2583-2592 [Abstract] [Full Text]  
  • Donnelly, J. J., Wahren, B., Liu, M. A. (2005). DNA Vaccines: Progress and Challenges. J. Immunol. 175: 633-639 [Abstract] [Full Text]  
  • Wiles, S., Ferguson, K., Stefanidou, M., Young, D. B., Robertson, B. D. (2005). Alternative Luciferase for Monitoring Bacterial Cells under Adverse Conditions. Appl. Environ. Microbiol. 71: 3427-3432 [Abstract] [Full Text]  
  • Wang, J., Thorson, L., Stokes, R. W., Santosuosso, M., Huygen, K., Zganiacz, A., Hitt, M., Xing, Z. (2004). Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis. J. Immunol. 173: 6357-6365 [Abstract] [Full Text]  
  • Hermanson, G., Whitlow, V., Parker, S., Tonsky, K., Rusalov, D., Ferrari, M., Lalor, P., Komai, M., Mere, R., Bell, M., Brenneman, K., Mateczun, A., Evans, T., Kaslow, D., Galloway, D., Hobart, P. (2004). A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. USA 101: 13601-13606 [Abstract] [Full Text]  
  • Romano, M., Denis, O., D'Souza, S., Wang, X.-M., Ottenhoff, T. H. M., Brulet, J.-M., Huygen, K. (2004). Induction of In Vivo Functional Db-Restricted Cytolytic T Cell Activity against a Putative Phosphate Transport Receptor of Mycobacterium tuberculosis. J. Immunol. 172: 6913-6921 [Abstract] [Full Text]  
  • Huygen, K. (2003). On the Use of DNA Vaccines for the Prophylaxis of Mycobacterial Diseases. Infect. Immun. 71: 1613-1621 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»